Tasly Pharmaceutical Group Co Ltd
SSE:600535

Watchlist Manager
Tasly Pharmaceutical Group Co Ltd Logo
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Watchlist
Price: 14.46 CNY
Market Cap: 21.6B CNY
Have any thoughts about
Tasly Pharmaceutical Group Co Ltd?
Write Note
Tasly Pharmaceutical Group Co Ltd
/
Balance Sheet
/
Cash & Cash Equivalents

Tasly Pharmaceutical Group Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tasly Pharmaceutical Group Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Cash & Cash Equivalents
¥3.4B
CAGR 3-Years
18%
CAGR 5-Years
12%
CAGR 10-Years
15%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash & Cash Equivalents
¥22.4B
CAGR 3-Years
74%
CAGR 5-Years
103%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash & Cash Equivalents
¥8.8B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash & Cash Equivalents
¥22.3B
CAGR 3-Years
16%
CAGR 5-Years
41%
CAGR 10-Years
22%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash & Cash Equivalents
¥14.1B
CAGR 3-Years
-9%
CAGR 5-Years
3%
CAGR 10-Years
24%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash & Cash Equivalents
¥391.7m
CAGR 3-Years
105%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tasly Pharmaceutical Group Co Ltd
Glance View

Market Cap
21.6B CNY
Industry
Pharmaceuticals

In the heart of China's bustling pharmaceutical landscape lies Tasly Pharmaceutical Group Co Ltd, a company intricately blending traditional herbal wisdom with cutting-edge scientific innovation. Founded in 1994, this enterprise has carved a niche in the competitive world of healthcare by focusing on Traditional Chinese Medicine (TCM) while also expanding into chemical medicine and biological drugs. Tasly's ecosystem thrives on the research, development, manufacturing, and marketing of its diverse product portfolio, which includes patent medicines, herbal injections, and health supplements. The crown jewel in its product lineup is the Compound Danshen Dripping Pill, a herbal medicine aimed at cardiovascular ailments, a testament to the company's commitment to merging ancient remedies with modern health solutions. By establishing an extensive distribution network both domestically and internationally, Tasly ensures its unique offerings reach a wide audience, catering not only to China's growing appetite for health products but also tapping into global markets hungry for alternative medicine solutions. Tasly’s financial engine leverages its broad spectrum of offerings, driven by both consumer demand for TCM and the pharmaceutical industry's appetite for innovation. The company invests significantly in research and development, with a particular emphasis on internationalizing TCM and obtaining global recognition for its products through clinical trials and partnerships. Such strategic actions bolster its competitive edge, positioning Tasly as a leader in an industry where tradition and science converge. Revenue streams are further diversified by the company's health management services and a growing footprint in biotechnology, showcasing its adaptability and forward-thinking approach. This intricate ballet of innovation and tradition enables Tasly Pharmaceutical Group to not just survive but thrive in an industry characterized by rapid advancements and shifting consumer paradigms.

Intrinsic Value
20.28 CNY
Undervaluation 29%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Tasly Pharmaceutical Group Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
3.4B CNY

Based on the financial report for Sep 30, 2024, Tasly Pharmaceutical Group Co Ltd's Cash & Cash Equivalents amounts to 3.4B CNY.

What is Tasly Pharmaceutical Group Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
15%

Over the last year, the Cash & Cash Equivalents growth was -60%. The average annual Cash & Cash Equivalents growth rates for Tasly Pharmaceutical Group Co Ltd have been 18% over the past three years , 12% over the past five years , and 15% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 211,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.